Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT

X Cahu; M Labopin; S Giebel; M Aljurf; S Kyrcz-Krzemien; G Socié; M Eder; F Bonifazi; D Bunjes; S Vigouroux; M Michallet; M Stelljes; T Zuckerman; J Finke; J Passweg; I Yakoub-Agha; D Niederwieser; G Sucak; Henrik Sengeløv; E Polge; A Nagler; J Esteve; M Mohty; Acute Leukemia Working Party of EBMT

doi:10.1038/bmt.2015.278

Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT

X Cahu, M Labopin, S Giebel, M Aljurf, S Kyrcz-Krzemien, G Socié, M Eder, F Bonifazi, D Bunjes, S Vigouroux, M Michallet, M Stelljes, T Zuckerman, J Finke, J Passweg, I Yakoub-Agha, D Niederwieser, G Sucak, Henrik Sengeløv, E PolgeA Nagler, J Esteve, M Mohty, Acute Leukemia Working Party of EBMT

27 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a therapeutic option for adult patients with T-cell ALL (T-ALL). Meanwhile, few allo-SCT data specific to adult T-ALL have been described thus far. Specifically, the optimal myeloablative conditioning regimen is unknown. In this retrospective study, 601 patients were included. Patients received allo-SCT in CR1, CR2, CR >2 or in advanced disease in 69%, 15%, 2% and 14% of cases, respectively. With an overall follow-up of 58 months, 523 patients received a TBI-based regimen, whereas 78 patients received a chemotherapy-based regimen including IV busulfan-cyclophosphamide (IV Bu-Cy) (n=46). Unlike patients aged ⩾35 years, patients aged <35 years who received a TBI-based regimen displayed an improved outcome compared with patients who received a chemotherapy-based regimen (5-year leukemia-free survival (LFS) of 50% for TBI versus 18% for chemo-only regimen or IV Bu-Cy regimens, P=10(-5) and 10(-4), respectively). In multivariate analysis, use of TBI was associated with an improved LFS (hazard ratio (HR)=0.55 (0.34-0.86), P=0.01) and overall survival (HR=0.54 (0.34-0.87), P=0.01) in patients aged <35 years. In conclusion, younger adult patients with T-ALL entitled to receive a myeloablative allo-SCT may benefit from TBI-based regimens.

Original language	English
Journal	Bone
Volume	51
Pages (from-to)	351-357
Number of pages	7
ISSN	8756-3282
DOIs	https://doi.org/10.1038/bmt.2015.278
Publication status	Published - 1 Mar 2016
Externally published	Yes

Keywords

Adult
Busulfan
Cyclophosphamide
Disease-Free Survival
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Humans
Male
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Registries
Survival Rate
Transplantation Conditioning
Whole-Body Irradiation
Comparative Study
Journal Article

Access to Document

10.1038/bmt.2015.278

bmt2015278.pdfFinal published version, 495 KB

https://www.nature.com/articles/bmt2015278.pdf

Cite this

Cahu, X., Labopin, M., Giebel, S., Aljurf, M., Kyrcz-Krzemien, S., Socié, G., Eder, M., Bonifazi, F., Bunjes, D., Vigouroux, S., Michallet, M., Stelljes, M., Zuckerman, T., Finke, J., Passweg, J., Yakoub-Agha, I., Niederwieser, D., Sucak, G., Sengeløv, H., ... Acute Leukemia Working Party of EBMT (2016). Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone, 51, 351-357. https://doi.org/10.1038/bmt.2015.278

Cahu, X, Labopin, M, Giebel, S, Aljurf, M, Kyrcz-Krzemien, S, Socié, G, Eder, M, Bonifazi, F, Bunjes, D, Vigouroux, S, Michallet, M, Stelljes, M, Zuckerman, T, Finke, J, Passweg, J, Yakoub-Agha, I, Niederwieser, D, Sucak, G, Sengeløv, H, Polge, E, Nagler, A, Esteve, J, Mohty, M & Acute Leukemia Working Party of EBMT 2016, 'Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT', Bone, vol. 51, pp. 351-357. https://doi.org/10.1038/bmt.2015.278

@article{9c2175a6a4834543a064ce542815b3bb,

title = "Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT",

abstract = "Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a therapeutic option for adult patients with T-cell ALL (T-ALL). Meanwhile, few allo-SCT data specific to adult T-ALL have been described thus far. Specifically, the optimal myeloablative conditioning regimen is unknown. In this retrospective study, 601 patients were included. Patients received allo-SCT in CR1, CR2, CR >2 or in advanced disease in 69%, 15%, 2% and 14% of cases, respectively. With an overall follow-up of 58 months, 523 patients received a TBI-based regimen, whereas 78 patients received a chemotherapy-based regimen including IV busulfan-cyclophosphamide (IV Bu-Cy) (n=46). Unlike patients aged ⩾35 years, patients aged <35 years who received a TBI-based regimen displayed an improved outcome compared with patients who received a chemotherapy-based regimen (5-year leukemia-free survival (LFS) of 50% for TBI versus 18% for chemo-only regimen or IV Bu-Cy regimens, P=10(-5) and 10(-4), respectively). In multivariate analysis, use of TBI was associated with an improved LFS (hazard ratio (HR)=0.55 (0.34-0.86), P=0.01) and overall survival (HR=0.54 (0.34-0.87), P=0.01) in patients aged <35 years. In conclusion, younger adult patients with T-ALL entitled to receive a myeloablative allo-SCT may benefit from TBI-based regimens.",

keywords = "Adult, Busulfan, Cyclophosphamide, Disease-Free Survival, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Male, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Registries, Survival Rate, Transplantation Conditioning, Whole-Body Irradiation, Comparative Study, Journal Article",

author = "X Cahu and M Labopin and S Giebel and M Aljurf and S Kyrcz-Krzemien and G Soci{\'e} and M Eder and F Bonifazi and D Bunjes and S Vigouroux and M Michallet and M Stelljes and T Zuckerman and J Finke and J Passweg and I Yakoub-Agha and D Niederwieser and G Sucak and Henrik Sengel{\o}v and E Polge and A Nagler and J Esteve and M Mohty and {Acute Leukemia Working Party of EBMT}",

year = "2016",

month = mar,

day = "1",

doi = "10.1038/bmt.2015.278",

language = "English",

volume = "51",

pages = "351--357",

journal = "Bone",

issn = "8756-3282",

publisher = "Elsevier",

}

TY - JOUR

T1 - Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation

T2 - a report from the acute leukemia working party of EBMT

AU - Cahu, X

AU - Labopin, M

AU - Giebel, S

AU - Aljurf, M

AU - Kyrcz-Krzemien, S

AU - Socié, G

AU - Eder, M

AU - Bonifazi, F

AU - Bunjes, D

AU - Vigouroux, S

AU - Michallet, M

AU - Stelljes, M

AU - Zuckerman, T

AU - Finke, J

AU - Passweg, J

AU - Yakoub-Agha, I

AU - Niederwieser, D

AU - Sucak, G

AU - Sengeløv, Henrik

AU - Polge, E

AU - Nagler, A

AU - Esteve, J

AU - Mohty, M

AU - Acute Leukemia Working Party of EBMT

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a therapeutic option for adult patients with T-cell ALL (T-ALL). Meanwhile, few allo-SCT data specific to adult T-ALL have been described thus far. Specifically, the optimal myeloablative conditioning regimen is unknown. In this retrospective study, 601 patients were included. Patients received allo-SCT in CR1, CR2, CR >2 or in advanced disease in 69%, 15%, 2% and 14% of cases, respectively. With an overall follow-up of 58 months, 523 patients received a TBI-based regimen, whereas 78 patients received a chemotherapy-based regimen including IV busulfan-cyclophosphamide (IV Bu-Cy) (n=46). Unlike patients aged ⩾35 years, patients aged <35 years who received a TBI-based regimen displayed an improved outcome compared with patients who received a chemotherapy-based regimen (5-year leukemia-free survival (LFS) of 50% for TBI versus 18% for chemo-only regimen or IV Bu-Cy regimens, P=10(-5) and 10(-4), respectively). In multivariate analysis, use of TBI was associated with an improved LFS (hazard ratio (HR)=0.55 (0.34-0.86), P=0.01) and overall survival (HR=0.54 (0.34-0.87), P=0.01) in patients aged <35 years. In conclusion, younger adult patients with T-ALL entitled to receive a myeloablative allo-SCT may benefit from TBI-based regimens.

AB - Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a therapeutic option for adult patients with T-cell ALL (T-ALL). Meanwhile, few allo-SCT data specific to adult T-ALL have been described thus far. Specifically, the optimal myeloablative conditioning regimen is unknown. In this retrospective study, 601 patients were included. Patients received allo-SCT in CR1, CR2, CR >2 or in advanced disease in 69%, 15%, 2% and 14% of cases, respectively. With an overall follow-up of 58 months, 523 patients received a TBI-based regimen, whereas 78 patients received a chemotherapy-based regimen including IV busulfan-cyclophosphamide (IV Bu-Cy) (n=46). Unlike patients aged ⩾35 years, patients aged <35 years who received a TBI-based regimen displayed an improved outcome compared with patients who received a chemotherapy-based regimen (5-year leukemia-free survival (LFS) of 50% for TBI versus 18% for chemo-only regimen or IV Bu-Cy regimens, P=10(-5) and 10(-4), respectively). In multivariate analysis, use of TBI was associated with an improved LFS (hazard ratio (HR)=0.55 (0.34-0.86), P=0.01) and overall survival (HR=0.54 (0.34-0.87), P=0.01) in patients aged <35 years. In conclusion, younger adult patients with T-ALL entitled to receive a myeloablative allo-SCT may benefit from TBI-based regimens.

KW - Adult

KW - Busulfan

KW - Cyclophosphamide

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Male

KW - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

KW - Registries

KW - Survival Rate

KW - Transplantation Conditioning

KW - Whole-Body Irradiation

KW - Comparative Study

KW - Journal Article

U2 - 10.1038/bmt.2015.278

DO - 10.1038/bmt.2015.278

M3 - Journal article

C2 - 26618548

SN - 8756-3282

VL - 51

SP - 351

EP - 357

JO - Bone

JF - Bone

ER -

Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT

Abstract

Keywords

Access to Document

Fingerprint

Cite this